Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Rieckmann

Showing results (11-20 of 129) with videos related to

Pageof 13
Sort By:
JMIR Rehabilitation and Assistive Technologies|March 17, 2022
The Association Between Actigraphy-Derived Behavioral Clusters and Self-Reported Fatigue in Persons With Multiple Sclerosis: Cross-sectional StudyPhilipp Gulde, Peter Rieckmann
Expert Review of Neurotherapeutics|March 19, 2008
Treating multiple sclerosis with monoclonal antibodiesMathias Buttmann, Peter Rieckmann
Journal of Clinical Medicine|June 2, 2021
Inpatient Rehabilitation: Prediction of Changes in Sensorimotor Performance in Multiple Sclerosis: A Pilot StudyPhilipp Gulde, Joachim Hermsdörfer, Peter Rieckmann
Multiple Sclerosis and Related Disorders|May 12, 2021
Sensorimotor function does not predict quality of life in persons with multiple sclerosisPhilipp Gulde, Joachim Hermsdörfer, Peter Rieckmann
Multiple Sclerosis International|June 14, 2021
Speed but Not Smoothness of Gait Reacts to Rehabilitation in Multiple SclerosisPhilipp Gulde, Joachim Hermsdörfer, Peter Rieckmann
Journal of Neuroimmunology|October 7, 2004
Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosisMathias Buttmann, Cornelia Merzyn, Peter Rieckmann
Therapeutic Advances in Neurological Disorders|December 25, 2010
Escalating immunotherapy of multiple sclerosisPeter Rieckmann, Anthony Traboulsee, Virginia Devonshire, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 20, 2010
The natural history of secondary progressive multiple sclerosisMarcus Koch, Elaine Kingwell, Peter Rieckmann, et al.
Journal of Neurochemistry|April 20, 2007
Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentrationMathias Buttmann, Alexander Lorenz, Andreas Weishaupt, et al.
Biomolecules & Therapeutics|October 17, 2013
The Changes of P-glycoprotein Activity by Interferon-γ and Tumor Necrosis Factor-α in Primary and Immortalized Human Brain Microvascular Endothelial CellsNa-Young Lee, Peter Rieckmann, Young-Sook Kang
Pageof 13

Showing results (11-20 of 129) with videos related to

Sort By:
Pageof 13
JMIR Rehabilitation and Assistive Technologies|March 17, 2022
The Association Between Actigraphy-Derived Behavioral Clusters and Self-Reported Fatigue in Persons With Multiple Sclerosis: Cross-sectional StudyPhilipp Gulde, Peter Rieckmann
Expert Review of Neurotherapeutics|March 19, 2008
Treating multiple sclerosis with monoclonal antibodiesMathias Buttmann, Peter Rieckmann
Journal of Clinical Medicine|June 2, 2021
Inpatient Rehabilitation: Prediction of Changes in Sensorimotor Performance in Multiple Sclerosis: A Pilot StudyPhilipp Gulde, Joachim Hermsdörfer, Peter Rieckmann
Multiple Sclerosis and Related Disorders|May 12, 2021
Sensorimotor function does not predict quality of life in persons with multiple sclerosisPhilipp Gulde, Joachim Hermsdörfer, Peter Rieckmann
Multiple Sclerosis International|June 14, 2021
Speed but Not Smoothness of Gait Reacts to Rehabilitation in Multiple SclerosisPhilipp Gulde, Joachim Hermsdörfer, Peter Rieckmann
Journal of Neuroimmunology|October 7, 2004
Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosisMathias Buttmann, Cornelia Merzyn, Peter Rieckmann
Therapeutic Advances in Neurological Disorders|December 25, 2010
Escalating immunotherapy of multiple sclerosisPeter Rieckmann, Anthony Traboulsee, Virginia Devonshire, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 20, 2010
The natural history of secondary progressive multiple sclerosisMarcus Koch, Elaine Kingwell, Peter Rieckmann, et al.
Journal of Neurochemistry|April 20, 2007
Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentrationMathias Buttmann, Alexander Lorenz, Andreas Weishaupt, et al.
Biomolecules & Therapeutics|October 17, 2013
The Changes of P-glycoprotein Activity by Interferon-γ and Tumor Necrosis Factor-α in Primary and Immortalized Human Brain Microvascular Endothelial CellsNa-Young Lee, Peter Rieckmann, Young-Sook Kang
Pageof 13